

Wales Cancer Biobank - Conditions of Supply

- All samples/data/images provided by WCB will be anonymised and will have a WCB number as the only identifier.
- Researchers do not need to apply to ethics for projects that are only using WCB anonymised samples; the WCB ethics approval from the Wales REC 3 gives deemed ethics to projects using samples that have been approved by the WCB External Review Panel. If an applicant requires identifiable data, they must first apply to HRA Research Ethics Service for project specific ethics. The samples do not need to be held under a Human Tissue Authority licence as they are anonymised and the project will have deemed ethics.
- A signed Material Transfer Agreement will be required prior to any sample/data/image supply. This will be with Cardiff University (as WCB host).
- Time to supply following application approval will vary depending upon the number and type of sample requested. Entire tissue blocks will not be issued unless there are exceptional circumstances that would require the whole block; sections or extracted material will be issued. If sample extraction is required, the quality and quantity of resulting nucleic acids cannot be guaranteed and may result in sample requirements not being fulfilled if deemed unsuitable for use.
- Project approval is valid for three (3) years from the date of supply of the first sample. If projects do not start within three (3) years of the date of approval, they will be deemed void and a new application will be required.
- Only samples and/or data detailed in the application may be collected and used for the purpose as set out in the approved application (as per MTA). Researchers may request to make minor amendments to an approved application within two (2) years of the approval date. Any changes in research question, methodology, tumour type or PI/research group must be submitted as a new application and will not be considered as an amendment.
- WCB will supply the minimum amount of sample necessary for projects and expects that samples will be exhausted at the conclusion of your project. No samples or portions of samples are expected to be returned to WCB. If any sample remains at the end of your project, the WCB MTA states that all samples must be disposed at the end of the approved application. It is your responsibility to ensure disposal compliant with the HTA code of conduct.
- Any derived products (e.g. PDX models) can be kept for future use at the end of the project but that use **MUST** be in line with the patients' original consent (i.e. for cancer related research). It is your responsibility to ensure relevant MTAs are in place for any future/onward use. Data received with the original sample **cannot** be passed on.
- WCB charges a fee to contribute towards recovering incurred costs. This fee is made up of several components. Please contact the WCB to confirm final costs or to cost a bespoke collection. All shipping costs will be the responsibility of the receiving researcher/group.
- WCB should be acknowledged as sample suppliers in any article, paper, poster, etc. generated from research carried out on samples supplied and WCB informed of the publication. Recommended wording to the methods or acknowledgement section is as follows: *"Biosamples were obtained from the Wales Cancer Biobank (DOI: <http://doi.org/10.5334/ojb.46>) which is a Health and Care Research Wales Infrastructure group, funded by Welsh Government and hosted by Cardiff University. Other investigators may have received specimens from the same subjects."*
- WCB will be asking for the return of raw data from all supplied projects, post publication or IP exploitation to collate in a data warehouse for future bioinformatics.